J.F. Barlow; M.W. Courtney; M. Trusheim. Pharmaceutical Executive, 04/2020
The reimbursement of emerging durable and potentially curative cell and gene therapies challenge US payers due to their high upfront costs. In addition, the lack of long-term clinical durability data amplifies uncertainties that complicate payer coverage and reimbursement determinations. These cell and gene therapy characteristics could negatively impact patient access and, ultimately, future developer innovation.